Science Gateway > Resources > Cluster of Differentiation Index

PROW: CD55
[PROW BAR]
PROW and IWHLDA present the GUIDE on:
CD55
Author: Bruce Loveland
Reviewers: Claire Harris; B. Paul Morgan
[GUIDE BAR]

ALTERNATE NAMES FOR CD55  

MAJOR LINKS FOR CD55  


FUNCTION
BIOCHEMICAL ACTIVITY OF CD55  

CELLULAR FUNCTION OF CD55  

DISEASE RELEVANCE OF CD55 AND FUNCTION OF CD55 IN INTACT ANIMAL  


STRUCTURE
MOLECULAR FAMILY FOR CD55  

MOLECULAR STRUCTURE OF CD55  

MOLECULAR MASS OF CD55  

CELL TYPEMW UNREDUCEDMW REDUCEDComment
Lymphocytes 70 kDa 80 kDa  
Erythrocytes** 55 kDa   The molecular mass of CD55 is about 5kDa less on erythrocytes than on nucleated cells. This is due to glycosylation differences

POST-TRANSCRIPTIONAL MODIFICATION OF CD55  

POST-TRANSLATIONAL MODIFICATION OF CD55  


MOLECULAR INTERACTIONS
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD55   - No information

SUBSTRATES FOR CD55   - No information

ENZYMES WHICH MODIFY CD55   - No information

LIGANDS FOR CD55 AND MOLECULES ASSOCIATED WITH CD55  

MOLECULECOMMENT
C3b / C3bBb convertase Binds through SCR2,3,4 - see note 1
C4b / C4b2a convertase Binds through SCR 2,3 - see note 1
Coxsackie viruses (B1, B3, B5) Receptor (probably via SCR1 & SCR3)
CD97 CD97 has recently been implicated as a ligand for CD55 [Hamann et al. 1996 J. Exp. Med. 184, 1185-1189
Echoviruses (type 7) Binding via SCR 2,3, 4 has been implicated [Clarkson et al. (1995) J. Virol. 69, 5497-5501]*
E. coli Dr-adhesins Receptor (via SCR3/4)
Enterovirus 70 Receptor
Protein tyrosine kinases lck and fyn, but not src

EXPRESSION
MAIN CELLULAR EXPRESSION OF CD55  
 
AUTHOR'S ADDITIONAL INSIGHTS ON CD55  
REAGENTS
CD55-SPECIFIC MABS NEWLY ASSIGNED AT SIXTH INTERNATIONAL WORKSHOP  
NAME(Workshop IDs)SOURCE or REFERENCECOMMENT
JS11 (N-L060) Bensussan  
67 (N-L063) Hogg  
F429D-9 (N-L120) Dignat-George  

SELECTION OF OTHER CD55-SPECIFIC REFERENCE MAB  

NAME(Workshop IDs)SOURCE or REFERENCECOMMENT
IA10 Kinoshita et al., 1985  
1H4 Coyne et al., 1992  
BRIC216 Holmes et al., 1989  
BU14 (B034) Hardie, D  
BU84 (B035) Hardie, D  
BU97 (B036) Hardie, D  

 
SELECTED REFERENCES ON CD55  

REVIEWS

1. Garratty G Blood group antigens as tumor markers, parasitic/bacterial/viral receptors, and their association with immunologically important proteins. Immunol Invest 1995 24:213 PubMed

2. Liszewski MK,Farries TC,Lublin DM,Rooney IA,Atkinson JP Control of the complement system. Adv Immunol 1996 61:201 PubMed

3. Lublin DM,Atkinson JP Decay-accelerating factor and membrane cofactor protein. Curr Top Microbiol Immunol 1990 153:123 PubMed

4. Nicholson-Weller A,Wang CE Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994 123:485 PubMed

5. Vanderpuye OA,Labarrere CA,McIntyre JA The complement system in human reproduction. Am J Reprod Immunol 1992 27:145 PubMed

PRIMARY CITATIONS

6. Bergelson JM,Mohanty JG,Crowell RL,St John NF,Lublin DM,Finberg RW Coxsackievirus B3 adapted to growth in RD cells binds to decay- accelerating factor (CD55). J Virol 1995 69:1903 PubMed

7. Brodbeck WG,Liu D,Sperry J,Mold C,Medof ME Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J Immunol 1996 156:2528 PubMed

8. Caras IW,Davitz MA,Rhee L,Weddell G,Martin DW Jr,Nussenzweig V Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 1987 325:545 PubMed

9. Clarkson NA,Kaufman R,Lublin DM,Ward T,Pipkin PA,Minor PD,Evans DJ,Almond JW Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol 1995 69:5497 PubMed

10. Finberg RW,White W,Nicholson-Weller A Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992 149:2055 PubMed

11. Hatanaka M,Seya T,Matsumoto M,Hara T,Nonaka M,Inoue N,Takeda J,Shimizu A Mechanisms by which the surface expression of the glycosyl- phosphatidylinositol-anchored complement regulatory proteins decay- accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines. Biochem J 1996 314:969 PubMed

12. Karnauchow TM,Tolson DL,Harrison BA,Altman E,Lublin DM,Dimock K The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol 1996 70:5143 PubMed

13. Medof ME,Lublin DM,Holers VM,Ayers DJ,Getty RR,Leykam JF,Atkinson JP,Tykocinski ML Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A 1987 84:2007 PubMed

14. Niehans GA,Cherwitz DL,Staley NA,Knapp DJ,Dalmasso AP Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996 149:129 PubMed

15. Pham T,Kaul A,Hart A,Goluszko P,Moulds J,Nowicki S,Lublin DM,Nowicki BJ dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay- accelerating factor. Infect Immun 1995 63:1663 PubMed

16. Post TW,Arce MA,Liszewski MK,Thompson ES,Atkinson JP,Lublin DM Structure of the gene for human complement protein decay accelerating factor. J Immunol 1990 144:740 PubMed

17. Shafren DR,Bates RC,Agrez MV,Herd RL,Burns GF,Barry RD Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995 69:3873 PubMed

18. Shenoy-Scaria AM,Kwong J,Fujita T,Olszowy MW,Shaw AS,Lublin DM Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J Immunol 1992 149:3535 PubMed

19. Spear GT,Lurain NS,Parker CJ,Ghassemi M,Payne GH,Saifuddin M Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 1995 155:4376 PubMed

20. Stoiber H,Pinter C,Siccardi AG,Clivio A,Dierich MP Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 1996 183:307 PubMed

21. Telen MJ Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Transfus Clin Biol 1995 2:277 PubMed

22. Thomas DJ,Lublin DM Identification of 5'-flanking regions affecting the expression of the human decay accelerating factor gene and their role in tissue-specific expression. J Immunol 1993 150:151 PubMed

23. Venneker GT,Das PK,Naafs B,Tigges AJ,Bos JD,Asghar SS Morphoea lesions are associated with aberrant expression of membrane cofactor protein and decay accelerating factor in vascular endothelium. Br J Dermatol 1994 131:237 PubMed

WWW RESOURCES


* indicates ammended by reviewer, ** indicates added by reviewer

Portions copyright by Garland Press and by the International Workshops on Human Leukocyte Differentiation Antigens; used with permission

Modified 10/14/99   mpr@mail.nih.gov